SABCS 2017: The latest in CDK inhibition in breast cancer

Circulating tumour cells may predict late recurrence in HR-positive breast cancer patients

Postmenopausal women who lose weight may have reduced breast cancer risk

Talazoparib vs physicians choice for patients with mBRCA1 breast cancer

CDK 4/6 inhibitors for older women with HR-positive breast cancer

Reducing risk of breast cancer recurrence and death with increased dose density

Breast cancer therapy resistance mediated by FGFR amplification

The significance of CEACAM 5 in metastases of triple negative breast cancer

Results of the MONALEESA 7 trial

The REACT trial: Celecoxib vs placebo for primary breast cancer

Rationale and recruitment in the PARTNER trial

The role of axiliary node dissection in modern breast cancer surgery

Anastrozole duration for post-menopausal breast cancer patients after 5 years of endocrine therapy

ER positive breast cancer: Screening for clinical variables to predict late distance disease recurrence

Predicting late breast cancer recurrence with screening assays

Individualising treatment of axillary nodes in breast cancer

The SOFT trial: Comparing adjuvant tamoxifen with ovarian function suppression via exemestane to tamoxifen alone

CDK 4/6 inhibitors for older women with HR-positive breast cancer

Talazoparib vs physicians choice for patients with mBRCA1 breast cancer

How can scalp-cooling reduce chemotherapy induced hair loss?

Acupuncture significantly reduces joint pain for breast cancer patients

Phase III trial data supports current standard 12-month adjuvant trastuzumab for HER2-positive breast cancer

Temporary ovarian suppression with hormone analogue may preserve fertility during breast cancer chemotherapy

Two years of extended anastrozole therapy as effective as five

Tandem duplicator phenotypes define 50% of triple negative breast cancers

Updated genomic screening tool for life-time breast cancer risk

Temporary ovarian suppression with hormone analogue may preserve fertility during breast cancer chemotherapy

Acupuncture significantly reduces joint pain for breast cancer patients

Immunotherapy shows early promise for patients with trastuzumab-resistant breast cancer

HR–positive advanced breast cancer: Ribociclib improved PFS for pre and perimenopausal women

HER2low invasive breast cancer: Trastuzumab offers no improvement for invasive disease free survival

Adjuvant trastuzumab did not improve outcomes for patients with HER2-low breast cancer

Increasing the dose intensity of chemotherapy may lower the risk of breast cancer recurrence and death